BioCorRx (BICX) Change in Accured Expenses (2011 - 2026)

BioCorRx has disclosed Change in Accured Expenses across 13 years of filings, most recently posting $253990.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $253990.0, up 1455.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $524496.0 (down 53.62% YoY), and the FY2025 annual result was $286839.0, down 80.11% from the prior year.
• Change in Accured Expenses came in at $253990.0 for Q1 2026 at BioCorRx, up from -$1.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $934022.0 in Q2 2025 to a low of -$1.5 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is $243702.0 (2023), against an average of $213186.9.
• Across the five-year window, Change in Accured Expenses plunged 24994.32% in 2025 and surged 1455.07% in 2026, its largest moves.
• BioCorRx's Change in Accured Expenses stood at $163767.0 in 2022, then climbed by 25.55% to $205612.0 in 2023, then plunged by 102.97% to -$6106.0 in 2024, then slumped by 24994.32% to -$1.5 million in 2025, then jumped by 116.58% to $253990.0 in 2026.
• The last three Change in Accured Expenses figures came in at $253990.0 (Q1 2026), -$1.5 million (Q4 2025), and $868743.0 (Q3 2025), per Business Quant data.